Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | KAT7 | O95251 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099600 | 1.00 | KCNH2 (0.37) | KCNH2GPR119METNR1D1PRKCQ | |
| SCHEMBL21099606 | 0.91 | KCNH2 (0.37) | KCNH2GPR119METNR1D1PRKCQ | |
| SCHEMBL28681459 | 0.89 | KCNH2 (0.38) | KCNH2GPR119METPRKCQBTK | |
| SCHEMBL21052498 | 0.88 | KRAS (0.34) | ALDH1A1LMNAMAPT | |
| SCHEMBL21050831 | 0.88 | KRAS (0.34) | ALDH1A1LMNAMAPT | |
| SCHEMBL21050833 | 0.88 | KRAS (0.34) | ALDH1A1LMNAMAPT | |
| SCHEMBL21099594 | 0.88 | KCNH2 (0.37) | KCNH2GPR119METPRKCQALDH1A1 | |
| SCHEMBL21099334 | 0.88 | GPR119 (0.36) | KCNH2GPR119ALDH1A1MAPT | |
| SCHEMBL28648177 | 0.88 | KCNH2 (0.37) | KCNH2GPR119METPRKCQALDH1A1 | |
| SCHEMBL21099361 | 0.86 | MET (0.39) | KCNH2GPR119METNR1D1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |